Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.88%
1,100.61
-9.73
-0.88%
—1,110.341,110.371,117.241,097.84——
SIXC
Communications
SIXC
Communications
SIXC
-1.33%
612.30
-8.24
-1.33%
—620.54620.54622.67611.42——
SIXE
Energy
SIXE
Energy
SIXE
+1.40%
1,175.46
+16.26
+1.40%
—1,159.201,160.591,177.621,156.21——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.39%
1,729.12
-24.32
-1.39%
—1,753.441,749.081,762.011,724.74——
SIXM
Financials
SIXM
Financials
SIXM
-0.63%
644.73
-4.07
-0.63%
—648.80649.58655.73643.68——
SIXR
Staples
SIXR
Staples
SIXR
-0.65%
827.09
-5.40
-0.65%
—832.49832.07833.09826.15——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-1.98%
214.82
-4.34
-1.98%
—219.16219.16219.19214.82——
SIXT
Technology
SIXT
Technology
SIXT
+0.06%
3,115.17
+1.81
+0.06%
—3,113.363,120.793,143.643,105.16——
SIXU
Utilities
SIXU
Utilities
SIXU
-1.75%
910.43
-16.24
-1.75%
—926.67927.99930.54910.08——
SIXV
Health care
SIXV
Health care
SIXV
-1.01%
1,474.50
-15.11
-1.01%
—1,489.611,499.051,499.051,474.35——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,405.87
-17.39
-0.72%
—2,423.262,438.162,443.462,399.83——
CRNX:NASDAQ
Crinetics Pharmaceuticals Inc
$38.90
-3.35%
(-1.35) 1D
$40.00
+2.83% (+1.10)
After hours
Closed: Apr 21, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRNX...
Open
$40.58
High
$40.58
Low
$38.68
Mkt. cap
4.07B
Avg. vol.
1.16M
Volume
0.00
52-wk high
$57.99
52-wk low
$25.83
EPS
-$4.95
Beta
0.30
Shares outstanding
104.70M
No. of employees
594
News stories
From sources across the web
Profile
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. Wikipedia
About Crinetics Pharmaceuticals Inc
CEO-
Employees594
FoundedNov 18, 2008
Headquarters-
SectorPharmaceutical industry
Websitecrinetics.com
Last report
Feb 26, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-1.29/ (-1.37 est.)USD
+5.69%beat
Revenue / Estimate
6.16M/ (4.81M est.)USD
+28.08%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
361.00K
1.03M
143.00K
6.16M
Cost of goods sold
76.24M
13.10M
90.46M
86.13M
Cost of revenue
76.24M
13.10M
90.46M
86.13M
Research and development expenses
-
67.20M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35.53M
49.84M
52.26M
53.70M
Operating expense
35.53M
117.04M
52.26M
53.70M
Total operating expenses
111.77M
130.14M
142.73M
139.83M
Operating income
-111.40M
-129.11M
-142.59M
-133.67M
Other non operating income
-203.00K
20.00K
-49.00K
-125.00K
EBT including unusual items
-96.77M
-115.64M
-130.09M
-122.64M
EBT excluding unusual items
-96.77M
-115.64M
-130.09M
-122.64M
Income tax expense
-
-
-
180.00K
Effective tax rate
-
-
-
-0.15%
Other operating expenses
-
-
-
-
Net income
-96.77M
-115.64M
-130.09M
-122.82M
Net profit margin
-26,807.20%
-11,216.00%
-90,972.73%
-1,993.43%
Earnings per share
-1.04
-1.23
-1.38
-1.29
Interest and investment income
14.83M
13.46M
12.54M
11.16M
Interest expense
-
-
-
-
Net interest expenses
14.83M
13.46M
12.54M
11.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
-110.48M
-128.15M
-141.57M
-132.67M
Gain or loss from assets sale
19.00K
23.00K
-
8.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer